MLTX (STOCKS)
MoonLake Immunotherapeutics Class A Ordinary Shares
$15.580800
-0.209200 (-1.32%)
Prev close: $15.790000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jorge Santos da Silva
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,116.28M
- Employees
- 100
- P/E (TTM)
- -4.69
- P/B (TTM)
- 3.48
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $229.20M |
| Research and Development | $187.22M |
| Other Operating Expenses | $41.98M |
| Operating Income/Loss | -$229.20M |
| Income/Loss From Continuing Operations After Tax | -$213.70M |
| Income/Loss From Continuing Operations Before Tax | -$213.54M |
| Income Tax Expense/Benefit | $404.20K |
| Net Income/Loss | -$213.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$3.20M |
| Net Income/Loss Attributable To Parent | -$210.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$211.94M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.32 |
| Diluted Earnings Per Share | -$3.32 |
| Basic Average Shares | 189,953,517 |
| Diluted Average Shares | 189,953,517 |
| Assets | $414.34M |
| Current Assets | $411.22M |
| Prepaid Expenses | $26.71M |
| Other Current Assets | $384.50M |
| Noncurrent Assets | $3.12M |
| Fixed Assets | $622.00K |
| Other Non-current Assets | $2.50M |
| Liabilities | $123.14M |
| Current Liabilities | $48.37M |
| Wages | $4.20M |
| Other Current Liabilities | $44.17M |
| Noncurrent Liabilities | $74.78M |
| Long-term Debt | $73.74M |
| Other Non-current Liabilities | $1.04M |
| Equity | $291.19M |
| Equity Attributable To Noncontrolling Interest | $2.29M |
| Equity Attributable To Parent | $288.91M |
| Liabilities And Equity | $414.34M |
| Net Cash Flow From Operating Activities | -$185.69M |
| Net Cash Flow From Operating Activities, Continuing | -$185.69M |
| Net Cash Flow From Investing Activities | $85.57M |
| Net Cash Flow From Investing Activities, Continuing | $85.57M |
| Net Cash Flow From Financing Activities | $73.75M |
| Net Cash Flow From Financing Activities, Continuing | $73.75M |
| Net Cash Flow | -$26.36M |
| Net Cash Flow, Continuing | -$26.36M |
| Comprehensive Income/Loss | -$216.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$3.24M |
| Comprehensive Income/Loss Attributable To Parent | -$213.07M |
| Other Comprehensive Income/Loss | -$2.60M |